We found that anti-VCAM1 antibody treatment and anti-CD49d antibody treatment significantly enhanced anti-tumor efficacy of iNKT cells in B16F10 tumor models (Fig. 8m–o). This evidence concerns the gene ITGA4 and neoplasm.